January 27-29, 2027 | Boston, MA

www.rnai-based-therapeutics.com

REGISTER BEFORE FRIDAY, NOVEMBER 13 TO SAVE UP TO $800

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

8th Annual

RNAi-Based Therapeutics Summit

Delivering Safer & More Potent RNAi Therapeutics

Advancing Extrahepatic RNAi Delivery to Improve Targeting Selectivity Across Obesity, Metabolic, Cardiovascular, Neurology & Oncology

Expert Speakers Include:



David Solomon
Chief Executive Officer
Thalia Therapeutics



Julia Alterman
Assistant Professor
UMass Chan Medical School



Marc Abrams
Chief Technology Officer
Sanegene Bio



Jimmy Weterings
Vice President & Head of Oligonucleotide Therapeutics
Bonito Biosciences



Nicole Lykens
Co-Founder & Chief Technology Officer
Valaya Bio



Pooja Gangras
Director, Molecule Discovery & Technology Licensing
Eli Lilly and Company

Proud to Partner With:

SynOligo BIOTECHNOLOGIES

CHEMGENES

+1 617 455 4188 info@hansonwade.com

www.rnaibased-therapeutics.com World RNA Series

hansonwade

Welcome to the 8th Annual RNAi-Based Therapeutics Summit

8th Annual RNAi-Based Therapeutics Summit
January 27-29, 2027 | Boston, MA

The RNAi field is entering a new era of growth, fueled by major pharma investments, billion-dollar partnerships, and promising clinical progress. With high-profile deals, including Sanegene Bio and Genentech's partnership worth up to $1.5 billion and Novartis' acquisition of Avidity Biosciences, alongside a growing body of positive clinical data, confidence in RNAi is rising rapidly as a transformative therapeutic modality.

Against this backdrop, the **8th RNAi-Based Therapeutics Summit** returns to unite the leaders driving this momentum and explore the next frontier of RNAi development, as the field focuses on unlocking extrahepatic delivery across high-value indications, including neurology, metabolic disease, obesity, cardiovascular disease, and oncology.

With delivery remaining the industry's greatest challenge, join **90+ industry peers** working across **oligo synthesis**, **chemistry**, **biology**, and **molecular design** in this intimate environment to learn, share and collaborate. Through showcasing the latest advances in antibody-oligonucleotide conjugates, nanoparticles, and other next-generation targeting technologies, now is your time to learn how to improve targeted delivery to a greater range of disease areas whilst balancing safety and efficacy, learning from leaders from **Sanegene Bio**, **Thalia Therapeutics**, **Judo Bio**, **Eli Lilly**, **Novo**, and many others!

As RNAi drug developers look to expand its application into larger chronic disease populations, there has never been a more important time to join the **8th RNAi-Based Therapeutics Summit** to accelerate the development of more potent and safer RNAi drugs.

What Our Speakers have to Say

"Hanson Wade conferences are the best place to be once you've moved beyond the academic grant world and into the early translation space, both in biotech and big pharma. Key personnel from leading organizations and companies gather to share common hurdles related to the topic at hand. Unlike academic conferences, the knowledge exchange here has a 'rising tide lifts all boats' spirit that's prominent throughout. I've never met a Hanson Wade conference attendee who didn't communicate in so many words, 'wow, that was kind of exceptional."

David Zebrowski, Founder and CEO, **GenKardia**

Key Benefits of Attending



Identify novel targets and extrahepatic delivery opportunities to expand clinical possibilities with **Eli Lilly** and **Novo**, and optimize next-generation oligonucleotide chemistry to improve potency, durability and PK/PD performance with **Bonito Biosciences** and **UMass Chan Medical School**



Overcome the Blood-Brain-Barrier to spearhead understanding of cell-specific delivery in the CNS with **Valaya Bio**. Gain insights into emerging approaches for crossing the blood-brain barrier and delivering RNAi therapeutics to difficult-to-reach neurological tissues.



Usher in the next era of delivery platforms with **Trinetra Therapeutics** showcasing how to develop tetravalent siRNAs to safely and effectively silence retinal disease, for an alternative approach to conventional antibody-based targeting, expanding the potential of RNAi beyond the liver.



Gain insights into RNAi approaches targeting cardiovascular and metabolic indications to tackle heart failure with **GenKardia** and discover how **Canary Cure** is unlocking adipose tissue as a target for next-generation obesity therapies.



Understand how leading RNAi developers are positioning assets for growth through expert perspectives from **Thalia Therapeutics** and **Madrigal Pharmaceuticals**, showing how to connect and develop relationships with investors and partners.

What's New For 2027?

8th Annual RNAi-Based Therapeutics Summit
January 27-29, 2027 | Boston, MA

Building on the industry's progress in extrahepatic delivery, the 2027 Summit expands beyond platform innovation to address the critical challenges of clinical translation, commercialization, and disease-specific extrahepatic application.

New agenda highlights include exclusive insights into novel RNAi technologies like aptamer-siRNA conjugates and tetravalent siRNAs and emerging opportunities across a range of disease indications. There will also be practical discussions sharing advice and experiences progressing candidates to clinical development, as well as strategic investment partnerships.

Key Sessions not to Miss



Unlocking Adipose Tissue as an RNAi Opportunity for Obesity Treatment

Raj Reddy will discuss how RNAi could transform obesity treatment through adipocyte-specific delivery strategies and novel metabolic targets outside traditional hormone-based approaches. This session will explore opportunities to establish durable therapies capable of addressing obesity and broader metabolic disease.

Raj Reddy, President, CEO & Founder, **Canary Cure**

1



Developing Tetravalent siRNAs for Efficient and Safe Silencing of Retinal Genes

Claudio Punzo will share preclinical data on tetravalent siRNA architectures engineered for retinal delivery. The session will explore chemistry design, retinal cell targeting, and safety and efficacy findings in non-human primates supporting future ophthalmology applications.

Claudio Punzo, Co-Founder & CSO, **Trinetra Therapeutics**

2




Leveraging Bispecific RNAi Approaches to Reduce Global Cardiovascular Risk

David Solomon will explore how bi-specific RNAi technologies are being developed to address cardiovascular risk in patients with atherosclerotic cardiovascular disease. The session will examine how simultaneously targeting multiple disease pathways could deliver superior reductions in cardiovascular burden and offer new opportunities beyond current standards of care.

David Solomon, CEO, **Thalia Therapeutics**

3




Understanding the Importance of Cell-Specific Delivery When Targeting the CNS

As investment in neurological RNAi therapies accelerates, Nicole Lykens will discuss one of the field's most important questions: how specific does delivery need to be? This session will assess whether enthusiasm for cell-selective targeting currently exceeds biological understanding, compare clinically validated transferrin-receptor approaches against emerging ligands, and explore where delivery technologies have the greatest potential to improve outcomes.

Fireside Chat with **Nicole Lykens**, Co-Founder & CTO, **Valaya Bio**

4



Pioneering RNAi Advancements to Push Boundaries in Patient Care

Marc Abrams will discuss SanegeneBio's unique oligonucleotide chemistry, its application to both liver and extrahepatic targets, and clinical data. Attendees will look at Sanegene Bio's LEAD platform is advancing siRNA design and chemistry, and how this is applied to their pipeline.

Marc Abrams, Chief Technology Officer, **Sanegene Bio**

5

New Companies for 2027 Include:

Lilly · BONITO biosciences · BAYER · Valaya Bio · THALIA · Madrigal · Bound Therapeutics · Trinetra Therapeutics

+1 617 455 4188 info@hansonwade.com
www.rnaibased-therapeutics.com World RNA Series
hansonwade

Your Expert Speakers

Pharma Leaders



Soren Ottosen
Senior Scientific Director
Bayer



Pooja Gangras
Director, Molecule Discovery & Technology Licensing
Eli Lilly and Company



Jihye Park
Associate Director
Novo

Biotech Innovators



Swetha Rajasekaran
Senior Scientist
Alltrna



Diego Piqueras-Losilla
Research & Development Project Leader
ARTHEx Biotech



Katherine Palozola
Senior Principal Investigator
Aro Biotherapeutics



Crystal Jin
Co-Founder & Chief Executive Officer
Bound Therapeutics



Raj Reddy
President, Founder & Chief Executive Officer
Canary Cure



Paul Lawrence
Executive Director, Bioscience Research
Biocogent



Jimmy Weterings
Vice President & Head of Oligonucleotide Therapeutics
Bonito Biosciences



David Jackson
Chief Executive Officer
Ceria Therapeutics



David Zebrowski
Founder & Chief Executive Officer
GenKardia



Eamon Comer
Senior Director Medicinal Chemistry
Judo Bio



Mark Barrett
Chief Business Officer
Madrigal Pharmaceuticals



Marc Abrams
Chief Technology Officer
Sanegene Bio



David Solomon
Chief Executive Officer
Thalia Therapeutics



Claudio Punzo
Co-Founder & Chief Scientific Officer
Trinetra Therapeutics



Michael Palfreyman
Non-Executive Director
Thalia Therapeutics



Nicole Lykens
Co-Founder & Chief Technology Officer
Valaya Bio

Academic Experts



Julia Alterman
Assistant Professor
UMass Chan Medical School



Thomas Ormsby
Postdoctoral Associate
UMass Chan Medical School

Pre-Conference Workshop Day
Wednesday, January 27

Registration & Coffee 8:00

Workshop A 9:00

Understanding Target Biology & Finding Novel Targets for RNAi to Advance Specific Delivery

As RNAi developers push beyond the liver, identifying the right receptor is crucial in achieving efficient and selective extra-hepatic delivery. This workshop will explore emerging approaches for discovering and validating novel receptors across a range of target tissues and disease indications. Attendees will examine why receptor expression alone is often insufficient for successful targeting, considering factors such as receptor internalisation, trafficking pathways and tissue accessibility. The session will also compare receptor-mediated delivery strategies against non-targeted approaches, helping attendees understand how different delivery technologies can improve specificity, potency and clinical translation.

Join this workshop to:

- Dive into the discovery and validation process for new receptors for cell-specific delivery
- Understand why receptor expression alone is insufficient for successful targeting
- Compare receptor-mediated versus non-targeted delivery approaches

Workshop Leaders



Pooja Gangras
Director - Molecule Discovery and Technology Licensing
Eli Lilly and Company



Jihye Park
Associate Director - Nucleic Acid Therapies
Novo

Lunch Break & Networking 12:00

Workshop B 13:00

Modifying Novel Oligonucleotide Chemistry for Improved PK/PD Effects

RNAi therapeutics are constantly expanding into increasingly challenging tissues and chronic disease indications, making optimising oligonucleotide chemistry essential for improving both therapeutic performance and commercial viability. This workshop will explore how novel chemical modifications can enhance stability, circulation time and tissue exposure, enabling more durable gene silencing and less frequent dosing. Attendees will examine emerging approaches designed to overcome key barriers such as RNA degradation, poor intracellular trafficking and limited endosomal escape, while balancing potency, safety and manufacturability. The session will also discuss how advances in chemistry are helping developers extend the clinical lifespan of RNAi assets, reduce dose burden for patients, unlock applications beyond traditional liver-directed therapies and, with an off-target strategy lens, how these decisions are assessed and defended through the regulatory process.

Join this workshop to:

- Assess chemical modifications that enhance durability and circulation time
- Improve therapeutic performance while reducing dose burden
- Extend the commercial and clinical viability of RNAi assets
- Overcome challenges like endosomal escape or RNA degradation

Workshop Leaders



Julia Alterman
Assistant Professor
UMass Chan Medical School



Jimmy Weterings
Vice President & Head of Oligonucleotide Therapeutics
Bonito Biosciences



Swetha Rajasekaran
Senior Scientist
Alltrna

End of Pre-Conference Workshop Day 16:00

Conference Day One
Thursday, January 28

8:00 **Registration & Coffee**



Soren Ottosen
Senior Scientific Director
Bayer

8.45 **Chair's Opening Remarks**

Ensuring Targeted Extra-Hepatic Delivery & Optimizing Novel Delivery Vehicles to Expand Therapeutic Reach of RNAi Beyond the Liver

9:00 **Fireside Chat: Defining the Next Frontier of RNAi Therapeutics to Target Beyond the Liver**

- Examining why extrahepatic delivery is the field's defining challenge
- Focusing investment and research on the right bottlenecks
- Defining the milestones that will signal the arrival of truly routine extrahepatic RNAi delivery



Paul Lawrence
Executive Director of Bioscience Research
Biocogent



David Jackson
Chief Executive Officer
Ceria Therapeutics



Thomas Ormsby
Postdoctoral Associate
UMass Chan Medical School
NEW DATA

9:30 **Developing Aptamer–siRNA Conjugates for Targeted Delivery to Muscle Moving Beyond Antibody Conjugates**

- Repurposing transferrin receptor 1 (TfR1)-binding aptamers as targeting ligands for systemic siRNA delivery
- Demonstrating selective and durable siRNA activity in skeletal muscle following a single systemic dose
- Establishing aptamer–siRNA conjugates as a promising platform for next-generation targeted oligonucleotide therapeutics

10:00 **Morning Break & Speed Networking**

Designing RNAi Technology for Cardiovascular Disease Targets to Improve Long-Term Patient Outcomes



David Solomon
CEO
Thalia Therapeutics

11:00 **Leveraging Bispecific RNAi Approaches to Reduce Global Cardiovascular Risk**

- Defining cardiovascular risk among a population with Atherosclerotic Cardiovascular Disease
- Using bispecific strategies to target appropriate cardiovascular receptors and markers
- Developing new RNAi medicines to reduce global cardiovascular risk



David Zebrowski
Founder and CEO
GenKardia

11:30 **Creating siRNA-Based Therapies for Broad Heart Failure Populations**

- Understanding disease-modifying mechanisms of action
- Recognizing where target identification meets safety profiles
- GenKardia's therapeutic position on treating heart failure

12:00 **Lunch Break & Networking**

Conference Day One
Thursday, January 28

Leveraging miRNA to Modulate Complex Disease Pathways



Paul Lawrence
Executive Director of Bioscience Research
Biocogent

1:00 **Adapting Modern MicroRNA Technology to Improve Skin Health**

- Identifying and developing miRNA-based active ingredients for topical delivery
- Surmounting the obstacles presented by the antagonistic relationship between RNA molecules and human skin
- Designing a delivery vehicle for miRNA-based actives that both protects and effectively delivers the RNA payload to viable cells



Diego Piqueras-Losilla
R&D Project Leader
ARTHEx Biotech

1:30 **Building the Next Generation of miRNA Therapeutics by Bridging Broader Biological Impact & Natural-Inspired Delivery to Advance Translational and Safe Therapeutic Innovations**

- Harnessing the potential of miRNA modulation as a disease-modifying therapeutic strategy with broad biological impact.
- Developing delivery methods inspired by natural mechanisms to improve the targeted distribution of oligonucleotides to metabolically active extrahepatic tissues, including the CNS, muscle, and heart.
- Addressing translational and safety challenges to build confidence in clinical development programs based on miRNA modulation.



2:00 **Afternoon Break & Poster Session**
Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in RNAi-based therapies and research advancements.
To submit a poster, please contact info@hansonwade.com

Expanding the Horizons of Disease Indications for RNAi Treatments



Nicole Lykens
Co-Founder and CTO
Valaya Bio



3:00 **Roundtable: Understanding the Importance of Cell-Specific Delivery When Targeting the CNS Addressing Cellular Complexity within the CNS**

- Addressing whether investment/funding enthusiasm surrounding cell-type specific delivery is running ahead of the biology and where it is justified
- Considering whether to keep optimizing transferrin receptor shuttles which are heavily clinically validated or make the riskier bet on novel ligands to tune delivery
- Locating where the biggest opportunity for the delivery community to make progress in cell-type specific delivery is (RMT, nanoparticles, RNAi chemistry), and the gaps that need to be filled to get there faster



Raj Reddy
President and CEO, Founder
Canary Cure

3:30 **Unlocking Adipose Tissue as an RNAi Opportunity for Obesity Treatment**

- Examine emerging metabolic pathways beyond GLP-1 approaches
- Explore advances in adipocyte-specific delivery technologies
- Enable transformative therapies for obesity and metabolic disease



Katherine Palozola
Senior Principal Investigator
Aro Biotherapeutics
NEW DATA

4:00 **Targeted Silencing of IFIH1/MDA5 with a CD71 Centyrin–siRNA Conjugate for the Treatment of Type 1 Diabetes**

- IFIH1/MDA5 is a genetically and mechanistically validated driver of Type 1 Diabetes, linking innate antiviral sensing to aberrant interferon signaling and autoimmune disease.
- Enabling cell-selective delivery and potent silencing of IFIH1/MDA5 using CD71-targeted Centyrin–siRNA conjugates, providing a strategy to modulate disease-relevant innate immune signaling
- Demonstrating pharmacodynamic and disease-modifying activity in pre-clinical studies, supporting continued development of targeted RNAi as a potential therapeutic approach for Type 1 Diabetes

4:30 **End of Day One**

Conference Day Two
Friday, January 29

8:00 **Registration & Coffee**



Michael Palfreyman
Non-Executive Director
Thalia Therapeutics

8.50 **Chair's Opening Remarks**

Understanding Success Stories to Spearhead the Future of RNAi Therapeutics

9:00 **Fireside Chat: Learning Lessons from Clinical-Stage RNAi Programs to Improve Study Progression from Preclinical Phases**

- Learn from companies advancing through late-stage development
- Identify recurring challenges and successful solutions
- Apply practical insights to accelerate program progression



Raj Reddy
President and CEO, Founder
Canary Cure



Soren Ottosen
Senior Scientific Director
Bayer



Marc Abrams
CTO
Sanegene Bio

10:00 **Pioneering Advancements to Push Boundaries in Patient Care**

- Explore the technologies emerging after the first wave of RNAi success
- Assess opportunities to further improve potency and durability
- Extend the commercial and clinical impact of tissue selective RNAi therapeutics

10:30 **Morning Break & Networking**

Understanding Key Factors to Develop Strong Investment & Funding Partnerships

11:00 **Panel Discussion: Securing Funding and Strategic Partnerships to Accelerate RNAi Innovation**

- Understand what investors and pharmaceutical partners look for
- Learn how to find and build relationships with investors/partners interested in your field
- Gain insights into the key conferences, partnering forums and networking platforms that are shaping investment and deal-making



Michael Palfreyman
Non-Executive Director
Thalia Therapeutics



Mark Barrett
Chief Business Officer
Madrigal Pharmaceuticals



David Jackson
Chief Executive Officer
Ceria Therapeutics

12:00 **Lunch Break & Networking**

Driving RNAi Beyond Established Indications to Address Unmet Patient Needs

1:00 **Developing Tetravalent siRNAs for Efficient and Safe Silencing of Retinal Genes**

- Exploring chemistries for retinal genes silencing
- Understanding target cells for disease alterations
- Establishing pre-clinical efficacies and safety in non-human primates



Claudio Punzo
Co-Founder and CSO
Trinetra Therapeutics
NEW DATA

Conference Day Two
Friday, January 29

1:30 Panel Discussion: Balancing Potency, Specificity & Therapeutic Index to Ensure Safe RNAi Therapies

- Understanding the drivers of RNAi-related toxicity
- Optimizing delivery, chemistry & dosing to improve therapeutic index
- Building confidence in safety as RNAi expands beyond the liver


Julia Alterman
Assistant Professor
UMass Chan Medical School


Jimmy Weterings
Vice President & Head of Oligonucleotide Therapeutics
Bonito Biosciences


Nicole Lykens
Co-Founder and CTO
Valaya Bio


Swetha Rajasekaran
Senior Scientist
Alltrna

2:30 Afternoon Break & Networking

Driving RNAi Beyond Established Indications to Address Unmet Patient Needs


Crystal Jin
Co-Founder and CEO
Bound Therapeutics

3:00 Establishing Multi-Target RNAi Strategies for Complex Tumour Biology

- Exploring dual and multi-gene silencing approaches designed to overcome pathway redundancy
- Addressing tumour adaptation and resistance mechanisms through combinatorial targeting
- Improving treatment responses across heterogeneous cancer populations


Eamon Comer
Senior Director
Medicinal Chemistry
Judo Bio

3:30 Targeting Megalin for Delivery of Genetic Medicines to the Kidney

- Employing Megalin-mediated selective delivery of oligonucleotides to kidney proximal tubule epithelial cells
- Developing potent, durable, kidney-specific gene silencing with cell-type precision
- Exploring emerging applications for kidney and systemic diseases.


Michael Palfreyman
Non-Executive Director
Thalia Therapeutics

4:00 Chair's Closing Remarks

4:15 End of the 8th RNAi-Based Therapeutics Summit

"The RNAi-Based Therapeutics Summit provides a unique opportunity to exchange insights on some of the key challenges shaping the next generation of RNAi therapeutics. I am looking forward to discussing emerging delivery strategies, translational approaches, and clinical development perspectives with experts across the field, while building meaningful connections and collaborations within the RNAi therapeutics community."

Diego Piqueras-Losilla, R&D Project Leader, **ARTHEx Biotech**

2027 Partners

Exhibitor Partner - SynOligo

Headquartered in Morrisville, NC, USA, Synoligo Biotechnologies is a Contract Research and Development Organization (CRDO) specialized in manufacturing complex and highly modified oligonucleotide for academic, biotech start-up and large pharmaceutical communities. Synoligo is a leading oligonucleotide manufacturing company providing high quality, cost-effective custom oligonucleotides at varying scales for research, diagnostic, and therapeutic applications.

www.synoligo.com

Exhibitor Partner - ChemGenes

Established in 1981, ChemGenes has consistently provided the highest quality Phosphoramidites and Solid Supports in the market. Our Massachusetts facility is setup for therapeutic grade phosphoramidites for GMP grade oligonucleotide manufacturing. Furthermore, ChemGenes carries the widest variety of modified phosphoramidites and solid supports currently used in various areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.

www.chemgenes.com

What Our Speakers Have to Say

"As RNAi therapeutics expand beyond the liver, new challenges in achieving effective and durable silencing across diverse tissues and cell populations are coming into focus, particularly in tissues with high cell turnover. I'm looking forward to the RNAi-Based Therapeutics Summit as an opportunity to exchange ideas on how advances in targeted delivery can address these challenges and continue to broaden the therapeutic reach of RNAi"

Katherine Palozola, Senior Principal Investigator, Biology, **Aro Biotherapeutics**

Get Involved



Thomas Conibear
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

8th Annual RNAi-Based Therapeutics Summit
January 27-29, 2027 | Boston, MA

Your Dedicated Platform to Connect with Decision-Makers Advancing RNAi Therapeutics

The **8th Annual RNAi-Based Therapeutics Summit** comes at a time when the RNAi field is entering a new phase of growth, with developers pushing beyond liver delivery into skeletal muscle, CNS, cardiovascular, obesity, kidney, retinal, and oncology applications. As a result, companies are actively seeking partners who can aid them in overcoming the industry's biggest challenges, providing services to improve translational predictability, oligonucleotide optimization, and manufacturing scalability.

Our audience is **actively evaluating CDMOs, CROs, oligonucleotide synthesis, analytical service providers, and translational model developers** that can help accelerate development timelines and reduce technical risk. This is your opportunity to engage directly with the scientists and decision-makers advancing the next generation of RNAi therapeutics and showcase how your technologies and services can help solve the delivery, development, and commercialization challenges facing the industry.

Raise Your Brand Awareness

Showcase your solutions to a highly targeted audience of RNAi, oligonucleotide, and nucleic acid therapeutic developers from leading pharma, biotech, and academia.


Build Relationships and Generate New Commercial Opportunities

Engage directly with decision-makers actively evaluating technologies and partnerships to advance RNAi programs.

Position Yourself at the Forefront of Innovation


Align your company with cutting-edge discussions around extrahepatic delivery, oligo chemistry, translational science, and chronic disease applications.

Seniority of Attendees



- C-Level - 37%
- Director/VP - 27%
- Scientist / Team Leader - 24%
- Other - 12%

Type of Companies Attending



- Drug Developers
- Academic & Research Institutes
- Service Providers

*Statistics Taken from 7th RNAi-Based Therapeutics Summit

Get Involved



Thomas Conibear
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.rnaibased-therapeutics.com

Tel: +1 617 455 4188

Email: info@hansonwade.com

DISCOVER the latest advances from new companies such as Thalia Therapeutics and Trinetra Therapeutics in extrahepatic RNAi delivery, antibody-oligonucleotide conjugates, nanoparticles, and next-generation targeting technologies.

BUILD your understanding of target biology, delivery optimization, and chronic disease applications, as well as CMC optimization and investment strategy.

ENGAGE with 90+ industry leaders from innovative biotech and pioneering pharma companies during dedicated networking, interactive workshop, and panel sessions.

Drug Developers*	Register by Friday, November 13 & Save up to $800	On the Door Price
Conference + Workshop Day	$3,707	$4,507
Conference Only	$2,749	$3,149

Academic & Research Institutes**	Register by Friday, November 13 & Save up to $800	On the Door Price
Conference + Workshop Day	$3,107	$3,907
Conference Only	$2,349	$2,749

Solution & Service Providers	Register by Friday, November 13 & Save up to $400	On the Door Price
Conference + Workshop Day	$4,997	$5,397
Conference Only	$3,599	$3,999

*To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com


Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Homewood Suites by Hilton Boston Seaport District
670 Summer Street, Boston, MA 02210
hilton.com/en/hotels/bossyhw-homewood-suites-boston-seaport-district/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom